BXRX - Baudax Bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Malvern,
United States
Type: Equity
BXRX price evolution
BXRX
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.36 | $1.42 | $3.8 | $5.26 |
| Short term investments | ||||
| Net receivables | $0.34 | |||
| Inventory | ||||
| Total current assets | $1.34 | $1.86 | $4.11 | $6.35 |
| Long term investments | ||||
| Property, plant & equipment | $6.55 | $6.72 | $0 | $1.56 |
| Goodwill & intangible assets | $12.7 | $12.74 | $2.13 | $2.13 |
| Total noncurrent assets | $19.25 | $19.46 | $2.96 | $3.69 |
| Total investments | ||||
| Total assets | $20.58 | $21.32 | $7.07 | $10.03 |
| Current liabilities | ||||
| Accounts payable | $7.82 | $5.83 | $3.84 | $3.93 |
| Deferred revenue | ||||
| Short long term debt | $5.57 | $6.47 | $6 | $5.6 |
| Total current liabilities | $19.05 | $20.46 | $12.37 | $21.46 |
| Long term debt | $2.53 | $2.3 | $1.43 | $1.52 |
| Total noncurrent liabilities | $2.73 | $2.5 | $2.01 | $12.81 |
| Total debt | $8.1 | $8.77 | $7.43 | $7.12 |
| Total liabilities | $21.78 | $22.95 | $14.38 | $34.27 |
| Shareholders' equity | ||||
| Retained earnings | -$189.3 | -$186.88 | -$179.5 | -$190.9 |
| Other shareholder equity | ||||
| Total shareholder equity | -$10.24 | -$10.68 | -$7.31 | -$24.24 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.26 | $15.89 | $30.34 | $17.74 |
| Short term investments | ||||
| Net receivables | $0.34 | $0.54 | $0.05 | |
| Inventory | $5 | $2.98 | ||
| Total current assets | $6.35 | $23.49 | $36.72 | $20.14 |
| Long term investments | ||||
| Property, plant & equipment | $1.56 | $5.01 | $5.63 | $5.55 |
| Goodwill & intangible assets | $2.13 | $23.8 | $26.38 | $28.53 |
| Total noncurrent assets | $3.69 | $29.78 | $32.02 | $34.08 |
| Total investments | ||||
| Total assets | $10.03 | $53.28 | $68.73 | $54.21 |
| Current liabilities | ||||
| Accounts payable | $3.93 | $1.47 | $3.65 | $0.27 |
| Deferred revenue | ||||
| Short long term debt | $5.6 | $2.22 | $1.02 | $0.32 |
| Total current liabilities | $21.46 | $15.65 | $18.13 | $7.71 |
| Long term debt | $1.52 | $6.31 | $8.76 | $0.46 |
| Total noncurrent liabilities | $12.81 | $24.41 | $65.4 | $63.22 |
| Total debt | $7.12 | $8.53 | $9.78 | $0.77 |
| Total liabilities | $34.27 | $40.05 | $83.53 | $70.93 |
| Shareholders' equity | ||||
| Retained earnings | -$190.9 | -$132.09 | -$112.32 | -$36.22 |
| Other shareholder equity | ||||
| Total shareholder equity | -$24.24 | $13.23 | -$14.8 | -$16.72 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.31 | |||
| Cost of revenue | $4.79 | |||
| Gross Profit | -$4.48 | |||
| Operating activities | ||||
| Research & development | $1.9 | $1.78 | $2.92 | $1.04 |
| Selling, general & administrative | $3.64 | $2.25 | $1.77 | $2.09 |
| Total operating expenses | $5.54 | $4.03 | $4.69 | $5.62 |
| Operating income | -$5.54 | -$4.03 | -$4.69 | -$10.11 |
| Income from continuing operations | ||||
| EBIT | -$1.93 | -$7.38 | $11.4 | -$9.25 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$1.93 | -$7.38 | $11.4 | -$9.25 |
| Income (for common shares) | -$1.93 | -$7.38 | $11.4 | -$9.25 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.27 | $1.08 | $0.49 | |
| Cost of revenue | $7.01 | $2.44 | $1.73 | |
| Gross Profit | -$5.74 | -$1.36 | -$1.24 | |
| Operating activities | ||||
| Research & development | $3.89 | $3.13 | $9.09 | $20.06 |
| Selling, general & administrative | $24.12 | $45.31 | $43.34 | $27.01 |
| Total operating expenses | $53.84 | $51.01 | $54.57 | $47.07 |
| Operating income | -$59.58 | -$52.38 | -$55.81 | -$47.07 |
| Income from continuing operations | ||||
| EBIT | -$58.8 | -$17.47 | -$74.74 | -$32.56 |
| Income tax expense | ||||
| Interest expense | $2.3 | $1.36 | ||
| Net income | ||||
| Net income | -$58.8 | -$19.77 | -$76.1 | -$32.56 |
| Income (for common shares) | -$58.8 | -$22.19 | -$76.1 | -$32.56 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Net income | -$1.93 | -$7.38 | $11.4 | -$9.25 |
| Operating activities | ||||
| Depreciation | $0.13 | $0 | $0 | $0.1 |
| Business acquisitions & disposals | $0.14 | |||
| Stock-based compensation | $0.25 | $0.2 | $0.19 | $0.23 |
| Total cash flows from operations | -$0.04 | -$0.07 | -$0.73 | -$3.78 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | |||
| Investments | -$0.09 | -$0.2 | ||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.02 | $3.51 | $4.31 | $4.73 |
| Net borrowings | -$0.55 | -$2.4 | -$1.1 | -$1.34 |
| Total cash flows from financing | $3.4 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.05 | -$2.39 | -$1.46 | -$0.39 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$58.8 | -$19.77 | -$76.1 | -$32.56 |
| Operating activities | ||||
| Depreciation | $2.16 | $2.82 | $2.55 | $0.48 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.4 | $4.79 | $9.34 | $5.46 |
| Total cash flows from operations | -$27.79 | -$49.27 | -$44.06 | -$50.04 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.2 | -$0.64 | -$1.48 |
| Investments | $0.01 | |||
| Total cash flows from investing | -$0.02 | -$0.19 | -$0.64 | -$1.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $20.83 | $42.88 | $50.82 | |
| Net borrowings | -$2.45 | $10.04 | ||
| Total cash flows from financing | $17.18 | $35.01 | $57.3 | $69.27 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$10.63 | -$14.45 | $12.6 | $17.74 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $310.00K |
|---|---|
| EBITDA | -$6.92M |
| EBIT | -$7.16M |
| Net Income | -$7.16M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -77.21% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -48.51% |
| ROE | 54.54% |
| Debt/Equity | -1.41 |
|---|---|
| Net debt/EBITDA | -3.10 |
| Current ratio | 0.07 |
| Quick ratio | 0.07 |